Metabolic Profiles of the Gut Microbiota in Patients with Different Stages of Metabolism Dysfunction-Associated Fatty Liver Disease

   Aim: to study the metabolic activity of the intestinal microbiota depending on the stage of metabolic dysfunction-associated fatty liver disease (MAFLD).

   Materials and methods. The study included 85 patients with MAFLD (27 patients with steatosis without steatohepatitis and fibrosis, 42 patients with steatohepatitis, 16 patients with cirrhosis as an outcome of MAFLD, Child — Pugh class A–B) and 20 healthy people who formed the control group. The level and spectrum of short-chain fatty acids (SCFA) were determined by gas-liquid chromatography.

   Results. It was found that patients with MAFLD at the stage of steatosis and cirrhosis of the liver have unidirectional changes in the metabolic activity of the intestinal microbiota. We established a decrease in the absolute concentrations of SCFA — their total content, the level of acetate, propionate, butyrate, a decrease in the level of isoacids. The SCFA profiles showed an increase in the proportion of acetate and a decrease in propionate and butyrate. Moreover, changes in the named parameters of SCFAs are aggravated with progression to liver cirrhosis. At the stage of steatohepatitis, we identified two subgroups of patients with different levels of metabolic activity of the microbiota. Patients whose microbiota metabolism for SCFA production was high had correspondingly elevated SCFA levels. And, on the contrary, patients in whom the metabolic activity of the microbiota was reduced were characterized by a steady decrease in SCFAs and disease progression to liver cirrhosis. In the study, we showed an inverse correlation between the calculated prognostic indices of NFS and FIB-4, elastography values with the total level of SCFA, the level of acetate, propionate, butyrate. Thus, a decrease in the content of SCFA for patients with MAFLD can be considered as a prognostic marker of an unfavorable course of liver disease.

1. Barber T.M., Hanson P., Weickert M.O. Metabolic-associated fatty liver disease and the gut microbiota. Endocrinol Metab Clin North Am. 2023;52(3):485–96. DOI: 10.1016/j.ecl.2023.01.004

2. Pabst O., Hornef M.W., Schaap F.G., Cerovic V., Clavel T., Bruns T. Gut-liver axis: Barriers and functional circuits. Nat Rev Gastroenterol Hepatol. 2023;20(7):447–61. DOI: 10.1038/s41575-023-00771-6

3. Maslennikov R., Poluektova E., Zolnikova O., Sedova A., Kurbatova A., Shulpekova Y., et al. Gut microbiota and bacterial translocation in the pathogenesis of liver fibrosis. Int J Mol Sci. 2023;24(22):16502. DOI: 10.3390/ijms242216502

4. Jayachandran M., Qu S. Non-alcoholic fatty liver disease and gut microbial dysbiosis-underlying mechanisms and gut microbiota mediated treatment strategies. Rev Endocr Metab Disord. 2023;24(6):1189–204. DOI: 10.1007/s11154-023-09843-z

5. Abenavoli L., Scarlata G.G.M., Scarpellini E., Boccuto L., Spagnuolo R., Tilocca B., et al. Metabolic-dysfunction-associated fatty liver disease and gut microbiota: From fatty liver to dysmetabolic syndrome. Medicina (Kaunas). 2023;59(3):594. DOI: 10.3390/medicina59030594

6. Pushpanathan P., Mathew G.S., Selvarajan S., Seshadri K.G., Srikanth P. Gut microbiota and its mysteries. Indian J Med Microbiol. 2019;37(2):268–77. DOI: 10.4103/ijmm.IJMM_19_373

7. Coppola S., Avagliano C., Calignano A., Berni Canani R. The protective role of butyrate against obesity and obesity-related diseases. Molecules. 2021;26(3):682. DOI: 10.3390/molecules26030682

8. Deng M., Qu F., Chen L., Liu C., Zhang M., Ren F., et al. SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. J Endocrinol. 2020;245(3):425–37. DOI: 10.1530/JOE-20-0018

9. Knudsen C., Neyrinck A.M., Lanthier N., Delzenne N.M. Microbiota and nonalcoholic fatty liver disease: Promising prospects for clinical interventions? Curr Opin Clin Nutr Metab Care. 2019;22(5):393–400. DOI: 10.1097/MCO.0000000000000584

10. Li Y., Qin G.Q., Wang W.Y., Liu X., Gao X.Q., Liu J.H., et al. Short chain fatty acids for the risk of diabetic nephropathy in type 2 diabetes patients. Acta Diabetol. 2022;59(7):901–9. DOI: 10.1007/s00592-022-01870-7

11. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121–40. DOI: 10.1007/s00125-016-3902-y

12. Associazione Italiana per lo Studio del Fegato (AISF); Società Italiana di Diabetologia (SID); Società Italiana dell’Obesità (SIO); Members of the guidelines panel; Coordinator; AISF Members; SID Members; SIO Members; Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis. 2022;54(2):170–82. DOI: 10.1016/j.dld.2021.04.029

13. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Y.V., Tkacheva O.N., Troshina E.A., et al. Clinical practice guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–40. (In Russ.) DOI: 10.22416/1382-4376-2022-32-4-104-140

14. Cao X., Zolnikova O., Maslennikov R., Reshetova M., Poluektova E., Bogacheva A., et al. Low short-chain-fatty-acid-producing activity of the gut microbiota is associated with hypercholesterolemia and liver fibrosis in patients with metabolic-associated (non-alcoholic) fatty liver disease. Gastrointest Disord. 2023;5:464–73. DOI: 10.3390/gidisord5040038

15. Cao X., Zolnikova O., Maslennikov R., Reshetova M., Poluektova E., Bogacheva A., et al. Differences in fecal short-chain fatty acids between alcoholic fatty liver-induced cirrhosis and non-alcoholic (metabolic-associated) fatty liver-induced cirrhosis. Metabolites. 2023;13(7):859. DOI: 10.3390/metabo13070859

16. Reshetova M.S., Zolnikova O.Yu., Ivashkin V.T., Ivashkin K.V., Appolonova S.A., Lapina T.L. Gut microbiota and its metabolites in pathogenesis of NAFLD. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(5):75–88. (In Russ.) DOI: 10.22416/1382-4376-2022-32-5-75-88

17. Ralli T., Saifi Z., Tyagi N., Vidyadhari A., Aeri V., Kohli K. Deciphering the role of gut metabolites in non-alcoholic fatty liver disease. Crit Rev Microbiol. 2023;49(6):815–33. DOI: 10.1080/1040841X.2022.2142091

18. Ney L.M., Wipplinger M., Grossmann M., Engert N., Wegner V.D., Mosig A.S. Short chain fatty acids: Key regulators of the local and systemic immune response in inflammatory diseases and infections. Open Biol. 2023;13(3):230014. DOI: 10.1098/rsob.230014

19. Tsai H.J., Hung W.C., Hung W.W., Lee Y.J., Chen Y.C., Lee C.Y., et al. Circulating short-chain fatty acids and non-alcoholic fatty liver disease severity in patients with type 2 diabetes mellitus. Nutrients. 2023;15(7):1712. DOI: 10.3390/nu15071712

20. Ji Y., Yin Y., Li Z., Zhang W. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). Nutrients. 2019;11(8):1712. DOI: 10.3390/nu11081712

21. Ji J., Wu L., Wei J., Wu J., Guo C. The gut microbiome and ferroptosis in MAFLD. J Clin Transl Hepatol. 2023;11(1):174–87. DOI: 10.14218/JCTH.2022.00136

22. Ganesan R., Gupta H., Jeong J.J., Sharma S.P., Won S.M., Oh K.K., et al. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease. Life Sci. 2023;322:121626. DOI: 10.1016/j.lfs.2023.121626

23. Rau M., Rehman A., Dittrich M., Groen A.K., Hermanns H.M., Seyfried F., et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018;6(10):1496–507. DOI: 10.1177/2050640618804444

24. Michail S., Lin M., Frey M.R., Fanter R., Paliy O., Hilbush B., et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91(2):1–9. DOI: 10.1093/femsec/fiu002

25. Backhed F., Manchester J.K., Semenkovich C.F., Gordon J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA. 2007;104(3):979–84. DOI: 10.1073/pnas.0605374104

26. Rahat-Rozenbloom S., Fernandes J., Gloor G.B., Wolever T.M. Evidence for greater production of colonic short-chain fatty acids in overweight than lean humans. Int J Obes (Lond). 2014;38(12):1525–31. DOI: 10.1038/ijo.2014.46

27. La Cuesta-Zuluaga D., Mueller N.T., Álvarez-Quintero R., Velásquez-Mejía E.P., Sierra J.A., Corrales-Agudelo V., et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients. 2018;11(1):51. DOI: 10.3390/nu11010051

28. Xiong J., Chen X., Zhao Z., Liao Y., Zhou T., Xiang Q. A potential link between plasma short-chain fatty acids, TNF-α level and disease progression in non-alcoholic fatty liver disease: A retrospective study. Exp Ther Med. 2022;24(3):598. DOI: 10.3892/etm.2022.11536

29. Sarkar A., Mitra P., Lahiri A., Das T., Sarkar J., Paul S., et al. Butyrate limits inflammatory macrophage niche in NASH. Cell Death Dis. 2023;14(5):332. DOI: 10.1038/s41419-023-05853-6